Bioanalysis of Oligonucleotides by LC-MS/MS

Modern medicine has long been built around a familiar strategy: identify a dysfunctional protein and attempt to inhibit, activate, or replace it. While this approach has transformed patient care across therapeutic areas, it also carries an inherent limitation — by the time a protein is active, the disease process is already in motion.

Oligonucleotide therapeutics shift this paradigm upstream.

Rather than targeting the final protein product, oligonucleotides intervene at the genetic and transcriptomic level, where disease truly begins. Designed as short, single- or double-stranded sequences of DNA or RNA — typically ranging from 10 to 1,000 nucleotides — these molecules are engineered to recognize and bind with extraordinary specificity to complementary DNA or RNA sequences. This precision allows them to selectively silence, modify, or regulate gene expression, offering a level of control that traditional small molecules and biologics often cannot achieve.

In this blog, we explore the bioanalysis of oligonucleotide therapeutics using LC–MS/MS, focusing on the scientific considerations that shape method development and validation. The insights shared here are authored by Veeda Lifesciences’ bioanalytical scientists, drawing from hands-on experience across complex oligonucleotide programs. Key insights, including the case study discussed here, have also been presented by Veeda experts at international scientific conferences, contributing to technical discussions among global peers and distinguished scientific audiences.

Molecular Architecture and Sequence-Driven Function

At their core, oligonucleotides are defined by a precise and highly ordered molecular architecture. Built from a repeating backbone of pentose sugars and phosphate groups, linked through phosphodiester bonds, and composed of nitrogenous bases — adenine, guanine, cytosine, and thymine (or uracil in RNA) — their biological activity is governed by sequence, structure, and chemical composition. Written and interpreted in the biological language of the 5′ to 3′ direction, each oligonucleotide encodes instructions that dictate its interaction, stability, and function within biological systems.

• Sugar backbone: deoxyribose (DNA) or ribose (RNA)
• Negatively charged phosphodiester linkage

Information encoded through base sequence and directionality

Therapeutic Modalities Enabled by Sequence Specificity

• Antisense oligonucleotides (ASOs) and RNA interference (RNAi) for gene silencing
• Anti-miRNAs for modulation of regulatory RNA networks
• Aptamers adopting defined three-dimensional structures for protein binding
• Gene-editing approaches, including CRISPR-based and prime editing strategies, aimed at permanent genetic modification

Together, these modalities are reshaping therapeutic strategies across a wide range of disease areas.

Analytical Considerations in Oligonucleotide Drug Development

As oligonucleotide therapeutics advance through development pipelines, accurate measurement and characterization within biological matrices becomes central to understanding their pharmacokinetics, metabolism, and biological behavior.

• Large molecular size and high polarity
• Multiple negative charges
• Sequence and length heterogeneity
• Chemical modifications and metabolite formation

Bioanalysis, particularly using LC–MS/MS, plays a critical role in addressing these complexities by enabling selective, structure-aware detection and quantification required to support translational and clinical development.

Bioanalytical Strategies for Oligonucleotide Method Development Quantification

Bioanalysis sits at the center of oligonucleotide drug development, a scientific discipline that determines whether pharmacokinetics, exposure–response relationships, and safety assessments can be interpreted with confidence.

Selecting an appropriate bioanalytical strategy is one of the earliest and most consequential decisions in oligonucleotide drug development. Unlike small molecules, where LC-MS/MS is often the default, oligonucleotides demand a more nuanced evaluation of analytical objectives, molecular characteristics, and regulatory expectations.

In practice, development programs typically evaluate three primary approaches — LC-MS/MS (or LC-HRMS), hybridization-based ligand-binding assays, and qPCR — each offering distinct strengths and limitations depending on the study phase and data requirements.

• LC-MS/MS (or LC-HRMS)

LC-MS/MS is selected when structural specificity and metabolic resolution are critical. Its ability to differentiate intact oligonucleotides from chain-shortened or chemically modified metabolites makes it particularly valuable during preclinical characterization and later clinical phases where biotransformation data are required.

• Hybridization-Based Ligand-Binding Assays (e.g., MSD-ECL)

Hybridization LBAs are frequently employed when ultra-high sensitivity and throughput are the primary drivers, particularly in early clinical plasma studies where metabolite resolution may be less critical.

• qPCR-Based Approaches

qPCR leverages amplification of target sequences to achieve exceptional sensitivity and is sometimes used when LC-MS/MS infrastructure is limited or when sequence-specific detection is required

• Hybrid LC–MS/MS

Hybrid LC–MS/MS combines sequence-specific hybridization capture with mass spectrometric detection, integrating the sensitivity advantages of ligand-binding assays with the structural selectivity of LC–MS/MS. In this workflow, oligonucleotides are first selectively enriched from biological matrices using complementary capture probes, followed by elution and quantitative analysis using LC–MS/MS.

A Comparative Overview

Why Method Development for Oligonucleotides Is Fundamentally Different

When compared to small molecule LC-MS/MS bioanalysis, the distinction becomes clear. Small molecules typically benefit from predictable ionization behaviour, established chromatographic conditions, and simpler fragmentation patterns. Oligonucleotides, by contrast, demand specialized chromatographic strategies, customized mass spectrometric tuning, and rigorous validation frameworks to ensure assay performance across accuracy, precision, selectivity, and stability parameters.

This complexity does not represent a limitation of LC-MS/MS, rather, it underscores the need for experience-driven method design, informed by an understanding of both molecular behaviour and regulatory expectations.

Case Study: LC–MS/MS Bioanalysis of a 20-mer Single-Stranded Oligonucleotide

The Analytical Problem

When Veeda Lifesciences undertook the bioanalytical method development for a 20-nucleotide single-stranded oligonucleotide (~7 kDa) in human plasma, the challenge was evident early in development. The molecule’s high polarity and polyanionic nature resulted in poor retention and limited selectivity under conventional reversed-phase LC conditions, complicating both chromatographic performance and quantitative reliability.

Sample Preparation

To address this, ion-pairing reagents were incorporated into the mobile phase, enabling meaningful retention and improved MS response. While effective, this approach introduced well-recognized operational risks — including response drift, extended column equilibration, and potential system contamination — necessitating a carefully controlled strategy rather than a purely instrumental solution.

Sample preparation played a pivotal role. An ion-exchange SPE protocol was optimized to improve extract cleanliness and recovery. However, during early runs, gradual response variability and changes in peak shape signaled the system’s sensitivity to ion-pair conditions and column history. Rather than treating these as isolated issues, Veeda implemented method-level operational controls as part of the analytical design.

Chromatography, Column Management & SOPs

• Dedicated columns were assigned for methods using ion‑pair reagents, preventing cross‑contamination with other applications.
• A column washing program was established: wash under initial mobile phase conditions for 2–3 hours (or more, if needed) after ion‑pair usage; avoid solvents beyond those used in the mobile phase.
• Seal mobile phase containers tightly and prepare fresh mobile phase daily to minimize volatilization of ion‑pair reagents (a root cause of response drift).
• These operational controls drastically improved variation and stabilized peak shape (demonstrated by chromatographic comparisons of analyte and internal standard before/after optimization).

Final Method Parameters (Highlights)

• Matrix: Human plasma; sample volume:2 mL
• LC System: Shimadzu LC‑40D X3; MS: Triple Quad (ESI)
• Column: RP C18, 110 Å, 50 × 4.6 mm
• Mobile Phase: Ion‑pair reagent (A) : Methanol (B), gradient; injection volume: 20 µL; total run: 12 min
• Internal Standards: Isotope‑labeled oligo (recommended for compensating matrix/ionization variability)
• Example gradient (Pump B %): 0–1.5 min: 20%; 6.0 min: 45%; 6.2–6.5 min: 90%; 7.0 min: back to 20% (re‑equilibration).

Representative chromatograms demonstrate double‑blank, LLOQ, and ULOQ performance with clean separation and consistent IS response after implementing the SOPs.

Validation Summary

• Calibration & Sensitivity
• Calibration range: 1–500 ng/mL (human plasma) with acceptable linearity.
• LLOQ QC (1.00 ng/mL): Inter‑run %CV ~ 9%, %Bias ~ −2.7% (indicative of robust low‑end precision/accuracy).
• Precision & Accuracy (Inter‑Day QC)
• Across LQC (3 ng/mL) to HQC (375 ng/mL), inter‑run %CV ranged ~3.3–9.3%, and %Bias stayed between −2.1% and +2.3%, satisfying typical bioanalytical acceptance criteria for precision and accuracy.
• Stability
• Autosampler (post‑preparative) stability: up to 95 hours
• Ambient extract stability: ~2 hours
• Freeze–thaw (−78±8 °C, −20±5 °C): 5 cycles
• Dry extract stability (−20±5 °C): ~165 hours
• Short‑term plasma stability (bench‑top): ~6 hours
• Whole blood stability: ~2 hours (room temp & wet ice)
• Long‑term plasma stability: ~157 days (−78±8 °C, −20±5 °C)

All stability studies fell within acceptable variability, supporting routine bioanalysis.

This case study illustrates a core principle of oligonucleotide bioanalysis: successful LC-MS/MS methods are not defined by instrumentation alone, but by an integrated understanding of molecular behavior, chromatographic chemistry, and operational discipline. At Veeda Lifesciences, this approach translates analytical complexity into reproducible, validation-ready data that supports confident decision-making throughout drug development